DOCSLIB.ORG

The 2016 Handbook of P S Y C H O T R O P I C D Ru G I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The 2016 Handbook of P S Y C H O T R O P I C D Ru G I DRUG INTERACTIONS.qxd 11/30/15 2:38 PM Page a The 2016 Handbook of P s y c h o t r o p i c D r u g Provided as an Educational Service by Glaxo SmithKline I n t e r a c t i o n s Pharmaceuticals C. Lindsay DeVane, PharmD Charles B. Nemeroff, MD, PhD ® Copyright ©2016 MedWorks Media Inc. Los Angeles, CA. All Rights Reserved DRUG INTERACTIONS.qxd 11/30/15 2:38 PM Page 2 Disclaimer This pocket re f e r ence is provided ®aPsyschia trya’s Number One Circulation service to medicine by the Portugese DivisionP u b l i c a t i o n of SmithKline Beecham Pharm a c e u t i c a l s . Sponsorship of this review does not imply the sponsor’s agreement with the views expressed herein. The 2016 Although every effort has been made to ensure that drug doses and other information are presented accurately in this Handbook of publication, the ultimate responsibility rests with the prescribing physician. Neither the publishers, the sponsor, nor the authors can P s y c h o t ro p i c be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are D ru g s t r ongly urged to consult any relevant primary literature. No claims or endorse- ments are made for any drug or compound I n t e r a c t i o n s currently under clinical investigation. Copyright ©2016, M e d Works Media Inc. All rights reserved, including the right of reproduction, in C. Lindsay DeVane, PharmD whole or in part, in any form. Charles B. Nemeroff, MD, PhD First Published in: D r. DeVane is professor of psychiatry and behavioral sciences at the Medical University of South Carolina in Charleston. Dr. Nemero ff is the Reunette W. Harris Professor and chairman of the Department of P s y c h i a t r y and Behavioral Sciences at Emory University School of Medicine in Atlanta, GA. No financial, academic, or other support of this work was acknowl- edged by the authors. C N S D r u g - D r ug Interactions Handbook • 2016 3 DRUG INTERACTIONS.qxd 11/30/15 2:38 PM Page 4 C o n t e n t s Index of Tables and Figure s INTRODUCTION 6 Major Components of Drug Disposition 10 CLASSIFICATION OF DRUG INTERACTIONS 7 Drug Elimination Sites During Absorption 12 Pharmacodynamic Drug Interactions 8 Protein Binding: Equilibrium of Drugs 14 Pharmacokinetic Drug Interactions 9 Recent Developments Relevant to Psychotropic Interactions Involving Absorption 9 Drug Interactions 40 Interactions Involving Distribution Major Psychotropic Drugs and Protein Binding 11 by Generic and Trade Name 40 Interactions Involving Metabolism Selected Drugs with Oxidative Metabolism Associated with CYP Enzymes 42 and/or Elimination 13 Selected Drugs with Conjugative Metabolism PREDICTION OF METABOLIC DRUG INTERACTIONS 15 Associated with Glucuronosyltransferase Enzymes 43 CYTOCHROME P-450 (CYP) ENZYMES 16 Questions/Issues to Consider in Interpreting CYP 1A2 17 Case Reports of Suspected Drug Interactions 43 CYP 2A 18 TCA Drug Interactions 44 CYP 2B 18 Newer Antidepressants and CYP 2C9/19 19 CYP Enzyme Inhibitory Potential 44 CYP 2D6 19 SSRI Drug Interactions 46 CYP 2E 20 Bupropion Drug Interactions 48 CYP 3A4 21 Nefazodone Drug Interactions 48 GLUCURONOSYLTRANSFERASES 22 Mirtazapine Drug Interactions 48 SPECIFIC DRUG INTERACTIONS 23 Venlafaxine Drug Interactions 50 Tricyclic Antidepressants 23 St. John’s Wort Drug Interactions 50 Selective Serotonin Reuptake Inhibitors 24 MAOI Drug Interactions 52 Other Newer Antidepressants 26 Lithium Drug Interactions 52 Monoamine Oxidase Inhibitors 27 Carbamazepine Drug Interactions 54 Lithium 28 Oxcarbazepine Drug Interactions 54 Other Mood Stabilizers 29 Valproate Drug Interactions 56 Psychostimulants 31 Lamotrigine Drug Interactions 56 Anxiolytics/Hypnotics 32 Topiramate Drug Interactions 56 Antipsychotic Agents 32 Methylphenidate Drug Interactions 58 Cholinesterase Inhibitors 34 Modafinil Drug Interactions 58 Anorectic/Anti-Obesity Agents 35 Benzodiazepine Drug Interactions 58 Methadone 36 Buspirone Drug Interactions 60 CONCLUSIONS 36 Phenothiazine Drug Interactions 60 BIBLIOGRAPHY 37 Zolpidem Drug Interactions 62 NOTES 70 Haloperidol Drug Interactions 62 Clozapine Drug Interactions 62 Risperidone Drug Interactions 64 Olanzapine Drug Interactions 64 Quetiapine Drug Interactions 66 Ziprasidone Drug Interactions 66 Selected Cholinesterase Inhibitors Drug Interactions 66 Selected Anorectic/Anti-Obesity Agents Drug Interactions 68 Selected Methadone Drug Interactions 68 4 5 DRUG INTERACTIONS.qxd 11/30/15 2:38 PM Page 6 Introduction tion of ziprasidone reflects the high level of activity in The present 2007 Guide to Psychotropic Dosing d r ug development for treatment of psychotic condi- Interactions is an update of the past edition. Since the tions. Additional new drugs in this category are cur- appearance of the 2004 Guide, new psychotropic dru g s rently being tested in clinical trials. Each of these com- have been introduced which have specific data related to pounds possesses a certain potential to interact with their potential drug interactions. Documentation contin- other drugs. This is especially true since psychoactive ues to appear at a steady pace in the literature of dru g d r ugs are generally highly metabolized compounds. interactions with commonly used psychotropics. As this L a b o r a t o r y methodologies developed in recent years guide is intended to serve an educational role for the psy- can identify the specific enzymes mediating various chiatrist-in-training, as well as non-psychiatric physicians metabolic pathways. This information can be used to less familiar with interactions of psychoactive drugs, the p r edict how a new drug will interact pharm a c o k i n e t i - bulk of the background discussion on drug metabolism cally with a variety of other drugs already marketed. and mechanisms of drug interactions remains unchanged. Some background knowledge of major dru g - m e t a b o l i z - For the repeat re a d e r, we have summarized import a n t ing enzymes is helpful in understanding how these pre- new findings on drug interactions appearing since the dictions are made. Of course, in vitro predictions must last update in Table 1. The interactions of three new psy- be confirmed with in vivo studies, but supporting clini- choactive drugs introduced recently to the market cal data may not be available for months or years. (oxcarbazepine, modafinil, and ziprasidone) are covere d This guide summarizes psychotropic drug interac- in Tables 17, 22, and 32. Other additions in the tables tions from several viewpoints. First, examples of phar- reflect new case re p o rts and further documentation of macokinetics will be discussed to aid the reader in d rug interactions. understanding how drugs may interact during the New knowledge related to the benefits of psychiatric course of their absorption and elimination from the d rug treatment results in earlier initiation of drug ther- b o d y. Secondly, because many interactions with psy- apy for some psychiatric disorders, and maintenance c h o t ropic drugs occur via specific interactions with the therapy is more and more commonplace during CYP system, this hepatic enzyme system will be asymptomatic periods. In fact, maintenance therapy described and the most important enzymes involved in for affective anxiety and psychotic disorders, often the metabolism or interactions of psychoactive dru g s continuing for years or decades, is now the accepted will be discussed. Some principles of drug interactions s t a n d a rd of care, especially for patients with a history operating through competitive inhibition of hepatic of re c u r rent episodes of illness. Long-term pharm a - enzymes will be explained, so that the reader may cotherapy re q u i res awareness and management of make informed judgments about the possibility of d rug interactions. an interaction. As the population ages, more drugs are prescribed on The bulk of the guide will be concerned with dru g a chronic basis for maintenance of health without tre a t- interactions that have been described with specific psy- ment of overt symptoms. Increasing numbers of patients choactive drug classes. The degree of documentation take one of the serum lipid-lowering compounds fro m varies for many interactions from theoretical conjec- the class of 3-hydroxy- 3-methylglutaryl co-enzyme A t u re, to clinical experience with patients, to well-estab- reductase inhibitors. These drugs can be taken for pri- lished re s e a rch outcomes. The sources of interaction m a ry prevention, re g a rdless of whether or not the patient data will be noted to help identify the appropriate level has previously experienced a vascular event such as a of confidence in the predicted consequences of com- m y o c a rdial infarction or stroke. With the exception of bining drugs in therapy. When possible, specific man- pravastatin, the drugs in this class are highly metabo- agement guidelines are provided to avoid or minimize lized by cytochrome P450 (CYP) 3A4, a hepatic enzyme some potentially negative interactions. The major psy- whose action can be inhibited by several antidepre s- choactive drugs, classified according to their primary sants. As will be explained later, some knowledge of how therapeutic indication, are listed in Table 2. Subsequent the major antidepressants interact with specific liver tables will list important drug interactions for each of enzymes allows the choice of an antidepressant that these classes. avoids such potential dru g - d rug interactions. New drugs to treat psychiatric illness have been Classification of Drug Interactions i n t roduced to clinical practice in recent years.
Load more

Recommended publications
  • Review of Market for Octane Enhancers
    May 2000 • NREL/SR-580-28193 Review of Market for Octane Enhancers Final Report J.E. Sinor Consultants, Inc. Niwot, Colorado National Renewable Energy Laboratory 1617 Cole Boulevard Golden, Colorado 80401-3393 NREL is a U.S. Department of Energy Laboratory Operated by Midwest Research Institute • Battelle • Bechtel Contract No. DE-AC36-99-GO10337 May 2000 • NREL/SR-580-28193 Review of Market for Octane Enhancers Final Report J.E. Sinor Consultants, Inc. Niwot, Colorado NREL Technical Monitor: K. Ibsen Prepared under Subcontract No. TXE-0-29113-01 National Renewable Energy Laboratory 1617 Cole Boulevard Golden, Colorado 80401-3393 NREL is a U.S. Department of Energy Laboratory Operated by Midwest Research Institute • Battelle • Bechtel Contract No. DE-AC36-99-GO10337 NOTICE This report was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or any agency thereof. Available electronically at http://www.doe.gov/bridge Available for a processing fee to U.S.
    [Show full text]
  • Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances 2017
    INTERNATIONAL NARCOTICS CONTROL BOARD Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances 2017 EMBARGO Observe release date: Not to be published or broadcast before Thursday, 1 March 2018, at 1100 hours (CET) UNITED NATIONS CAUTION Reports published by the International Narcotics Control Board in 2017 The Report of the International Narcotics Control Board for 2017 (E/INCB/2017/1) is supplemented by the following reports: Narcotic Drugs: Estimated World Requirements for 2018—Statistics for 2016 (E/INCB/2017/2) Psychotropic Substances: Statistics for 2016—Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2017/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2017 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2017/4) The updated lists of substances under international control, comprising narcotic drugs, psychotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E-1339 P.O. Box 500 1400 Vienna Austria In addition, the following may be used to contact the secretariat: Telephone: (+43-1) 26060 Fax: (+43-1) 26060-5867 or 26060-5868 Email: [email protected] The text of the present report is also available on the website of the Board (www.incb.org).
    [Show full text]
  • Organocatalytic Asymmetric N-Sulfonyl Amide C-N Bond Activation to Access Axially Chiral Biaryl Amino Acids
    ARTICLE https://doi.org/10.1038/s41467-020-14799-8 OPEN Organocatalytic asymmetric N-sulfonyl amide C-N bond activation to access axially chiral biaryl amino acids Guanjie Wang1, Qianqian Shi2, Wanyao Hu1, Tao Chen1, Yingying Guo1, Zhouli Hu1, Minghua Gong1, ✉ ✉ ✉ Jingcheng Guo1, Donghui Wei 2 , Zhenqian Fu 1,3 & Wei Huang1,3 1234567890():,; Amides are among the most fundamental functional groups and essential structural units, widely used in chemistry, biochemistry and material science. Amide synthesis and trans- formations is a topic of continuous interest in organic chemistry. However, direct catalytic asymmetric activation of amide C-N bonds still remains a long-standing challenge due to high stability of amide linkages. Herein, we describe an organocatalytic asymmetric amide C-N bonds cleavage of N-sulfonyl biaryl lactams under mild conditions, developing a general and practical method for atroposelective construction of axially chiral biaryl amino acids. A structurally diverse set of axially chiral biaryl amino acids are obtained in high yields with excellent enantioselectivities. Moreover, a variety of axially chiral unsymmetrical biaryl organocatalysts are efficiently constructed from the resulting axially chiral biaryl amino acids by our present strategy, and show competitive outcomes in asymmetric reactions. 1 Key Laboratory of Flexible Electronics & Institute of Advanced Materials, Jiangsu National Synergetic Innovation Center for Advanced Materials, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, China. 2 College
    [Show full text]
  • Organic Light-Emitting Diode (OLED) OLED Materials Hole Transport Layer (HTL) / Electron Blocking Layer (EBL)
    Organic Light-EmittingOrganic Light-Emitting DiodeHole Transport(OLED) Layer (HTL) / Diode (OLED) _ OLED Materials Electron Blocking Layer (EBL) Organic Light-Emitting Diode (OLED) _ OLED Materials Hole Transport Layer (HTL) / Electron Blocking Layer (EBL) LT-E101 NPB LT-E105 Spiro-TPD N,N'-Bis(naphthalen-1-yl)-N,N'-bis(phenyl)-benzidine N,N'-Bis(3-methylphenyl)-N,N'-bis(phenyl)-2,7-diamino- CAS No. : 123847-85-8 9,9-spirobifluorene Grade : Sublimed, > 99.5% (HPLC) CAS No. : 1033035-83-4 : Grade : Sublimed, > 99% (HPLC) Organic Light-Emitting Diode (OLED) _ OLED Materials Formula C44H32N2 M.W. : 588.74 g/mole Formula : C51H38N2 UV : 339 nm (in THF) M.W. : 678.86 g/mole PL : 450 nm (in THF) UV : 379 nm (in THF) TGA : > 350 °C (0.5% weight loss) PL : 416 nm (in THF) TGA : > 280 °C (0.5% weight loss) N N N N LT-E102 β-NPB N,N'-Bis(naphthalen-2-yl)-N,N'-bis(phenyl)-benzidine Spiro-NPB CAS No. : 139255-17-7 LT-E106 Grade : Sublimed, > 99% (HPLC) N,N'-Bis(naphthalen-1-yl)-N,N'-bis(phenyl)-2,7-diamino- 9,9-spirobifluorene Formula : C44H32N2 M.W. : 588.74 g/mole CAS No. : 932739-76-9 UV : 349 nm (in THF) Grade : Sublimed, > 99% (HPLC) PL : 416 nm (in THF) Formula : C57H38N2 TGA : > 330 °C (0.5% weight loss) M.W. : 750.93 g/mole UV : 380 nm (in THF) PL : 453 nm (in THF) TGA : > 360 °C (0.5% weight loss) N N N N LT-E103 TPD N,N'-Bis(3-methylphenyl)-N,N'-bis(phenyl)-benzidine CAS No.
    [Show full text]
  • Interplay Between Gating and Block of Ligand-Gated Ion Channels
    brain sciences Review Interplay between Gating and Block of Ligand-Gated Ion Channels Matthew B. Phillips 1,2, Aparna Nigam 1 and Jon W. Johnson 1,2,* 1 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA; [email protected] (M.B.P.); [email protected] (A.N.) 2 Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA * Correspondence: [email protected]; Tel.: +1-(412)-624-4295 Received: 27 October 2020; Accepted: 26 November 2020; Published: 1 December 2020 Abstract: Drugs that inhibit ion channel function by binding in the channel and preventing current flow, known as channel blockers, can be used as powerful tools for analysis of channel properties. Channel blockers are used to probe both the sophisticated structure and basic biophysical properties of ion channels. Gating, the mechanism that controls the opening and closing of ion channels, can be profoundly influenced by channel blocking drugs. Channel block and gating are reciprocally connected; gating controls access of channel blockers to their binding sites, and channel-blocking drugs can have profound and diverse effects on the rates of gating transitions and on the stability of channel open and closed states. This review synthesizes knowledge of the inherent intertwining of block and gating of excitatory ligand-gated ion channels, with a focus on the utility of channel blockers as analytic probes of ionotropic glutamate receptor channel function. Keywords: ligand-gated ion channel; channel block; channel gating; nicotinic acetylcholine receptor; ionotropic glutamate receptor; AMPA receptor; kainate receptor; NMDA receptor 1. Introduction Neuronal information processing depends on the distribution and properties of the ion channels found in neuronal membranes.
    [Show full text]
  • Hydroxydopamine Lesions of the Nucleus Accumbens and the Mglur2/3 Agonist LY379268
    Neuropsychopharmacology (2003) 28, 1440–1447 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Toluene-Induced Locomotor Activity is Blocked by 6- Hydroxydopamine Lesions of the Nucleus Accumbens and the mGluR2/3 Agonist LY379268 1,3 2 ,1 AC Riegel , SF Ali , ED French* 1Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA; 2Neurochemistry Laboratory, Division of Neurotoxicology, National Center for Toxicological Research/US FDA, Jefferson, AR, USA The abuse of volatile inhalants remains a prominent, yet poorly understood, form of substance abuse among youth. Nevertheless, the identification of a mechanism underlying the reinforcing properties of inhalants has been hampered by the lack of a clearly identifiable neural substrate upon which these chemicals act. One ingredient that is common to many abused inhalants is toluene, an organic solvent that is self-administered by nonhuman primates and rodents. Most drugs of abuse have been found to elicit forward locomotion in rats, an effect owing to the activation of mesoaccumbal dopamine (DA) pathways. Thus, the present study was undertaken using two different approaches to determine whether toluene-induced locomotor hyperactivity is also ultimately dependent upon DA neurotransmission in the mesolimbic nucleus accumbens (NAC). Here we report on the effects of 6-hydroxydopamine (6-OHDA) lesions of the NAC or pretreatment with the metabotropic mGlu2/3 receptor agonist LY379268 on toluene-induced locomotor activity. Both procedures, which are known to alter neurotransmission within the NAC, significantly attenuated toluene’s locomotor stimulatory effects. These results provide strong support for a central mechanism of action of inhalants, which in the past has been more typically attributed to general nonspecific mechanisms throughout the brain.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Inhalant Abuse Pediatric Care
    CLINICAL REPORT Guidance for the Clinician in Rendering Inhalant Abuse Pediatric Care Janet F. Williams, MD, Michael Storck, MD, and the Committee on Substance Abuse and Committee on Native American Child Health ABSTRACT Inhalant abuse is the intentional inhalation of a volatile substance for the purpose of achieving an altered mental state. As an important, yet-underrecognized form of substance abuse, inhalant abuse crosses all demographic, ethnic, and socioeco- nomic boundaries, causing significant morbidity and mortality in school-aged and older children. This clinical report reviews key aspects of inhalant abuse, empha- sizes the need for greater awareness, and offers advice regarding the pediatrician’s role in the prevention and management of this substance abuse problem. TYPES OF CHEMICALS AND PRODUCTS ABUSED The term “inhalant” encompasses a wide range of pharmacologically diverse substances that readily vaporize. Most other substances of abuse are classified by grouping together substances that share a specific central nervous system action or perceived psychoactive effect, but inhalant substances that are abused are grouped by having a common route of drug use. Inhalant abuse, sometimes referred to as solvent or volatile substance abuse, can be better understood when the expansive list of inhalants is classified into 3 groups on the basis of what is currently known pharmacologically: group I includes volatile solvents, fuels, and anesthetics; group II includes nitrous oxide; and group III includes volatile alkyl nitrites (Table 1). This classification is also consistent with reported differences in user populations, patterns of abuse, and associated problems seen clinically.1–3 Drugs that do not www.pediatrics.org/cgi/doi/10.1542/ readily vaporize at room temperature, such as cocaine, heroin, nicotine, or alcohol, peds.2007-0470 can also be abused through inhalation, but characteristic pharmacologic properties doi:10.1542/peds.2007-0470 distinguish these substances from inhalants.
    [Show full text]
  • The Effects of the Morphine Analogue Levorphanol on Leukocytes: Metabolic Effects at Rest and During Phagocytosis
    The effects of the morphine analogue levorphanol on leukocytes: Metabolic effects at rest and during phagocytosis Nancy Wurster, … , Penelope Pettis, Sharon Lebow J Clin Invest. 1971;50(5):1091-1099. https://doi.org/10.1172/JCI106580. Studies on bacteria have suggested that morphine-like drugs have effects on the cell membrane. To determine the effect of this class of drugs on a mammalian cell, we selected the rabbit peritoneal exudate granulocyte, which undergoes striking membrane changes during phagocytosis. We examined the effect in vitro of the morphine analogue, levorphanol on phagocytosis and metabolism by granulocytes incubated with and without polystyrene particles or live Escherichia coli. Levorphanol (1 or 2 mmoles/liter) decreased: (a) acylation of lysolecithin or lysophosphatidylethanolamine in the medium (which is stimulated about two-fold during phagocytosis) both at rest (40%) and during phagocytosis (60%); (b) uptake of latex particles and Escherichia coli, as judged by electron microscopy; (c) killing of live Escherichia coli (10-fold); (d) 14 14 + CO2 production from glucose-1- C during phagocytosis by at least 80%; (e) K content of granulocytes (35%); (f) oxidation of linoleate-1-14C by 50%, and its incorporation into triglyceride by more than 80%. However, levorphanol stimulated 2 to 3-fold the incorporation of linoleate-1-14C or palmitate-1-14C into several phospholipids. Glucose uptake, lactate production, and adenosine triphosphate (ATP) content are not affected by the drug. Thus, levorphanol does not appear to exert its effects through generalized metabolic suppression. Removal of levorphanol by twice resuspending the granulocytes completely reverses all inhibition. In line with observations on bacteria, it appears that the complex effects of levorphanol on […] Find the latest version: https://jci.me/106580/pdf The Effects of the Morphine Analogue Levorphanol on Leukocytes METABOLIC EFFECTS AT REST AND DURING PHAGOCYTOSIS NANcY WuRsTE, PETER ELSBACH, ERIc J.
    [Show full text]
  • Consultation Documents
    WHO Drug Information Vol. 29, No. 3, 2015 Consultation documents To receive draft monographs by email please contact Mrs Wendy Bonny ([email protected]), specifying that you wish to be added to the electronic mailing list. The International Pharmacopoeia Carbamazepinum Carbamazepine This is a draft proposal for The International Pharmacopoeia (Working document QAS/15.608, July 2015). The working document with line numbers and tracked changes is available for comment at www.who.int/medicines/areas/quality_safety/quality_assurance/projects/en/. Please address any comments to: World Health Organization, Quality Assurance and Safety: Medicines, Dr Herbert Schmidt, 1211 Geneva 27, Switzerland; fax: +41 22 791 4730; email: [email protected]. [Note from the Secretariat. It is proposed to revise the monograph on Carbamazepine in The International Pharmacopoeia.] [Note from the editor. In accordance with WHO editorial policy the text reproduced below does not include tracked changes. Changes from the current monograph are indicated by insert and delete in the working document available at the above-mentioned web address.] Molecular formula. C15H12N2O Relative molecular mass. 236.3 Graphic formula. Chemical name. 5H-Dibenz[b,f]azepine-5-carboxamide; CAS Reg. No. 298-46-4. Description. A white to almost white, crystalline powder. Solubility. Practically insoluble in water; sparingly soluble in acetone; soluble in ethanol (~750 g/L) TS; freely soluble in dichloromethane. Category. Antiepileptic. 352 WHO Drug Information Vol. 29, No. 3, 2015 Consultation documents Additional information. Carbamazepine exhibits polymorphism. The acceptable crystalline form is anhydrous polymorph form III1. It corresponds to carbamazepine RS. Storage. Carbamazepine should be kept in a tightly closed container.
    [Show full text]
  • Direct Analysis of Psilocin and Muscimol in Urine Samples Using Single Drop Microextraction Technique In-Line with Capillary Electrophoresis
    molecules Article Direct Analysis of Psilocin and Muscimol in Urine Samples Using Single Drop Microextraction Technique In-Line with Capillary Electrophoresis Anna Poliwoda * , Katarzyna Zieli ´nskaand Piotr P. Wieczorek Faculty of Chemistry, University of Opole, Oleska 48, 45-042 Opole, Poland * Correspondence: [email protected]; Tel.: +48-77452-7116 Academic Editors: Mihkel Koel and Marek Tobiszewski Received: 20 February 2020; Accepted: 25 March 2020; Published: 29 March 2020 Abstract: The fully automated system of single drop microextraction coupled with capillary electrophoresis (SDME-CE) was developed for in-line preconcentration and determination of muscimol (MUS) and psilocin (PSC) from urine samples. Those two analytes are characteristic active metabolites of Amanita and Psilocybe mushrooms, evoking visual and auditory hallucinations. Study analytes were selectively extracted from the donor phase (urine samples, pH 4) into the organic phase (a drop of octanol layer), and re-extracted to the acidic acceptor (background electrolyte, BGE), consisting of 25 mM phosphate buffer (pH 3). The optimized conditions for the extraction procedure of a 200 µL urine sample allowed us to obtain more than a 170-fold enrichment effect. The calibration curves 1 were linear in the range of 0.05–50 mg L− , with the correlation coefficients from 0.9911 to 0.9992. The limit of detections was determined by spiking blank urine samples with appropriate standards, 1 1 i.e., 0.004 mg L− for PSC and 0.016 mg L− for MUS, respectively. The limits of quantification varied 1 1 from 0.014 mg L− for PSC and 0.045 mg L− for MUS.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]